posted
Medical Services Receives Regulatory Approval in Saudi Arabia PR Newswire - November 15, 2006 12:47 PM ET
Related Quotes Symbol Last Chg MSITF Trade 0.0002 0.00 Real time quote.
Medical Services International Inc. (OTC: MSITF) is pleased to announce that it has received regulatory permission to sell its VScan HIV test kit in Saudi Arabia. Testing completed by regulatory agencies shows that once again the VScan test kit exceeded 99% accuracy in terms of sensitivity and specificity. The Company is currently negotiating several large orders with distributors in the Middle East. Market studies and information obtained from regulatory agencies shows that the market in the Middle East will exceed 1,000,000 test kits per year.
In regard to Europe, the VScan HIV test kit is currently approved by regulatory agencies in Russia, Ukraine, Balkans and India. The Company through its distributor has applied for approval in the European Union (CE). Once approval in the European Union is obtained, the Company will have extensive coverage all over Europe, Asia and the Middle East. VScan test kits are currently being shipped into 17 countries in the above noted areas. With the anticipated CE approval that number will increase significantly. Worldwide, the Company is currently shipping into 29 countries. Within the next year, the Company expects to increase the number of countries it is shipping VScan test kits to greater than 60.
About VScan
The VScan rapid test kit is a single use, disposable, accurate, cost effective, easy to use, test for the screening of HIV1&2, Hepatitis B&C, Tuberculosis (TB), Dengue Fever, West Nile, Syphilis, Malaria and Prostate Cancer. The kits cannot be sold in Canada.
Medical Services International Inc. trades in the United States on the NQB Pinksheets under the symbol "MSITF." For further information, please contact Robert Talbot at (780) 430 6363 or http://www.medicalservicesintl.com or http://www.minerva-biotech.com .
NOTE: Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause results to differ materially. Such risks, uncertainties and other factors include but are not limited to new economic conditions, risk in product development, market acceptance of new products and continuing product demand, level of competition and other factors described in Company reports and other filings with regulatory bodies.
posted
Medical Services International Completes Testing of VScan Hepatitis C Test Kit in the United States PR Newswire - December 13, 2006 12:52 AM ET
Related Quotes Symbol Last Chg MSITF Trade 0.0001 0.00 Real time quote.
Medical Services International Inc (Pinksheets: MSITF) is pleased to announce that it has completed testing of its VScan Hepatitis C test kit in the United States. The test results shows that the VScan Hepatitis C test kit met or exceeded required regulatory standards in the United States. In early 2007, the Company will begin the process to apply for regulatory approval in the United States.
It is reported in published literature that there are over 200 million people that have Hepatitis C and do not know it. Market studies show that there will be a large demand for a rapid test kit for Hepatitis C that can be used in the privacy of your own home. It is expected that once regulatory approval is obtained in the United States the market will exceed 5.0 million kits per year.
About VScan
The VScan rapid test kit is a single use, easy to use, test for the screening of HIV 1&2, Hepatitis B&C, Tuberculosis (TB), Dengue Fever, West Nile, Syphilis, Malaria and Prostate Cancer. The kits cannot be sold in Canada.
Medical Services International Inc. trades in the United States on the NQB Pinksheets under the symbol "MSITF". For further information, please contact Robert Talbot at (780) 430 6363 or www.medicalservicesintl.com or www.minerva-biotech.com.
NOTE: Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause results to differ materially. Such risks, uncertainties and other factors include but are not limited to new economic conditions, risk in product development, market acceptance of new products and continuing product demand, level of competition and other factors described in Company reports and other filings with regulatory bodies.
posted
Medical Services International to Begin Shipping to Greece PR Newswire - December 19, 2006 1:01 PM ET
Related Quotes Symbol Last Chg MSITF Trade 0.0001 0.00 Real time quote.
Medical Services International Inc. (OTC: MSITF) is pleased to announce that it has received orders for its VScan HIV, Hepatitis C, and Tuberculosis (TB) test kits from Greece. The initial orders will be shipped in January 2007. It has been indicated that there will be follow up orders in excess of 500,000 kits over the next 6 months.
The VScan test kits have done very well in testing in Europe. As a result of the independent test results obtained significant interest from Europe is being generated by the test kits. The Company expects 2007 to be a significant growth year.
About VScan
The VScan rapid test kit is a single use, disposable, accurate, cost effective, easy to use, test for the screening of HIV 1&2, Hepatitis B&C, Tuberculosis (TB), Dengue Fever, West Nile, Syphilis, Malaria and Prostate Cancer. The kits cannot be sold in Canada.
Medical Services International Inc. trades in the United States on the NQB Pinksheets under the symbol "MSITF". For further information, please contact Robert Talbot at (780) 430 6363 or http://www.medicalservicesintl.com or http://www.minerva-biotech.com .
NOTE: Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause results to differ materially. Such risks, uncertainties and other factors include but are not limited to new economic conditions, risk in product development, market acceptance of new products and continuing product demand, level of competition and other factors described in Company reports and other filings with regulatory bodies.
posted
Answer from the National Institute For Communicable Diseases. I asked if they could confirm this PR.
Maybe it's all true after all!!! wouldn't that be something !!!
Dear Mr. Xxxxx, yes I can confirm that the NICD evaluated the kit and the results are correct. The company should be able to provide you with a report that we provided to them for your scrutiny. The results however, are not necessarily unique to the kit and does not mean there is necessarily a competitive advantage against other kits.
Medical Services Completes Further Testing of Its VScan HIV Test Kit With Excellent Results
EDMONTON, Alberta, Dec. 27 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pinksheets: MSITF) is pleased to announce that it has completed additional testing of its VScan HIV test kit with the National Institute For Communicable Diseases. The regulatory agency tested 500 VScan HIV test kits with the following test results: Sensitivity- 100%, Specificity- 100%. It is very rare for a test kit to test with such accuracy. The final report also refers to ease of performance with a rating of 'very easy to use' and suitability for use rating as 'very suitable.' A report of this magnitude from an agency with the excellent reputation of the National Institute For Communicable Diseases confirms the reliability of the VScan HIV test kit.
This report once again demonstrates the accuracy of the VScan HIV test kit. The many excellent independent test results are now being included in new updated marketing brochures and will be included on the new website that is currently being constructed. It is felt that reports of this magnitude combined with additional approvals in more countries combined with the new website will significantly increase kit sales in 2007. The Company is looking forward to an exceptional new year.
About VScan
The VScan rapid test kit is a single use, disposable, accurate, cost effective, easy to use, test for the screening of HIV 1&2, Hepatitis B&C, Tuberculosis (TB), Dengue Fever, West Nile, Syphilis, Malaria and Prostate Cancer. The kits cannot be sold in Canada.
NOTE: Certain statements in this press release are 'forward-looking statements' within the meaning of the Private Securities Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause results to differ materially. Such risks, uncertainties and other factors include but are not limited to new economic conditions, risk in product development, market acceptance of new products and continuing product demand, level of competition and other factors described in Company reports and other filings with regulatory bodies.
Dear Sir/Madam, I would be quite prepared to respond to your enquiry on the above but would like to better understand the nature of your enquiry.
Thank you,
Adrian Puren
Deputy Director
National Institute for Communicable Diseases
The views expressed in this email are, unless otherwise stated, those of the author and not those of the National Health Laboratory Services or its management. The information in this e-mail is confidential and is intended solely for the addressee. Access to this e-mail by anyone else is unauthorized. If you are not the intended recipient, any disclosure, copying, distribution or any action taken or omitted in reliance on this, is prohibited and may be unlawful. Whilst all reasonable steps are taken to ensure the accuracy and integrity of information and data transmitted electronically and to preserve the confidentiality thereof, no liability or responsibility whatsoever is accepted if information or data is, for whatever reason, corrupted or does not reach its intended destination.
IP: Logged |
posted
Medical Services International Inc. (Pinksheets: MSITF) wishes to announce that it has continued to expand its distribution network. Currently the company has distributors in 42 countries worldwide and expects to increase its network to 49 countries by the end of April, 2007. Based on distribution agreements the Company anticipates selling in excess of 6.3 million test kits this year. There will be significant increase in demand for the Malaria and Dengue Fever kits this year.
The Company will continue to expand its distribution network during the year. The Company continues to expand its product base. Testing is being completed on an additional 15 products. The website is being upgraded to include the new products.
The Company continues to make progress on its financial statements and will publish them as soon as they are complete.
About VScan
The VScan rapid test kit is a single use, disposable, accurate, cost effective, easy to use, test for the screening of HIV 1&2, Hepatitis B&C, Tuberculosis (TB), Dengue Fever, West Nile, Syphilis, Malaria and Prostate Cancer. The kits cannot be sold in Canada.
NOTE: Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause results to differ materially. Such risks, uncertainties and other factors include but are not limited to new economic conditions, risk in product development, market acceptance of new products and continuing product demand, level of competition and other factors described in Company reports and other filings with regulatory bodies.
Medical Services International Inc.
SOURCE Medical Services International Inc.
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
